CBLL vs DXCM
CBLL: Ceribell develops wearable EEG systems and AI-powered software for rapid, automated seizure detection and brain monitoring in acute care settings. DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data.
Side-by-side fundamentals
| Metric | CBLL | DXCM | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $17.64 | $73.37 | |
| Market cap as of 2026-07-31 | $673M | $28.5B | |
| P/E as of 2026-07-31 | n/a | 30.66 | |
| PEG as of 2026-07-31 | n/a | 1.26 | |
| Net margin as of 2026-07-31 | -63.5% | +19.3% | DXCM higher |
| Gross margin as of 2026-07-31 | +87.7% | +63.4% | CBLL higher |
| Operating margin as of 2026-07-31 | -68.3% | +21.4% | DXCM higher |
| ROE as of 2026-07-31 | -38.2% | +33.8% | DXCM higher |
| ROA as of 2026-07-31 | -30.9% | +13.4% | DXCM higher |
| Debt / equity as of 2026-07-31 | 0.14 | 0.44 | CBLL lower |
| Revenue growth (YoY) as of 2026-07-31 | +29.3% | +16.1% | CBLL higher |
| Revenue CAGR (3y) SEC XBRL | +40.3% | +17.0% | CBLL higher |
| Beta as of 2026-07-31 | 1.52 | 1.41 | |
| 1-year return as of 2026-07-30 close | +18.2% | -17.6% | CBLL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.